Buttons, jar lids, the first ten minutes of the morning. One gummy before bed — 20 mg of Q-Actin®, the dose and the timing the published trials used.
60-day refund — opened or not, nothing to send back · Free US shipping · The five papers sent with your order
One VFlex gummy, about thirty minutes before bed — the timing the trials used.
Notice the first ten minutes. That’s where this either earns its place or doesn’t.
MitoV+ and Vioni+ in the morning — the Complete Cellular Ritual.
In a sponsor-funded, 180-day randomised, double-blind, multi-centre trial with no placebo arm — an active comparison against glucosamine-chondroitin rather than against nothing — 20 mg of Q-Actin® a day improved joint comfort, stiffness and function (WOMAC) by 70.3% against its own starting point, while the 2,700 mg glucosamine-chondroitin group improved 32.81% against theirs.
Three things we will say plainly about that trial, because you will not find them in most supplement marketing: it is a pooled multicentre pilot rather than a single registration study; its own abstract and results text do not agree on every number; and it dosed 10 mg twice daily, where VFlex gives you 20 mg once in the evening — the same daily total on a different schedule.
122 people, six months. Each figure is that group's improvement against its own baseline. p<0.05.
One hundred and thirty-five times less material. More than double the movement.
Watch what happened between day 90 and day 180.
The glucosamine group reached −23.7% at ninety days and then essentially stopped: three more months of capsules bought them another nine percentage points. That is what a structural building block does — it saturates, and then there is nowhere left to go.
The Q-Actin® group was at −38.3% at ninety days and −70.3% at a hundred and eighty. It nearly doubled in the half of the trial where the other arm had already finished.
Most people quit a joint supplement at month three, because month three is where most of them stop paying. This one was still climbing.†
The comparison above tells you how Q-Actin® measures against the standard of the category. It does not tell you how it measures against nothing, because there was no placebo arm in it. We would rather say that than let you assume otherwise.
So: a second trial, three arms, placebo-controlled, 101 people, the same 180 days. The effect held, and it tracked with dose — more Q-Actin®, more movement.
We do not have a headline percentage to print from that one, so we are not printing one.†
Fair. A culinary cucumber carries only negligible traces of the compound that matters here. Q-Actin® comes from selected agricultural cultivars, concentrated twelve to one, and standardised so that more than 1% of what's in the gummy is idoBR1 — the rare iminosugar amino acid the research is actually about.
That is the difference between a salad and a dose. One is lunch. The other is 20 mg of a standardised active with a 180-day human trial behind it.
Glucosamine and chondroitin are structural: raw material, delivered in bulk, in the hope the joint uses it. It is a patient strategy, and it does nothing about why the cartilage is being broken down in the first place.
idoBR1 works at the signalling layer. It binds receptors on the cells that manage cartilage, which keeps an inflammatory switch called NF-κB from being thrown, which means the cell never issues the instruction to over-produce MMP-3 — the enzyme that actually degrades cartilage matrix.
A signal does not need to saturate anything. That is why 20 mg is enough, and why it fits in one gummy instead of six capsules.
Not more bricks. Fewer wrecking balls.
Mechanism established in laboratory cell models on the active marker idoBR1. VFlex supports joint comfort and mobility; it is not a treatment for any joint condition.
The raw material has a file. The thing you actually swallow usually does not. That is the quiet gap in almost every supplement you have ever bought.
Fifty-six people, twelve weeks, double-blind against placebo — in gummy form. Manual dexterity was measured directly with the Nine-Hole Peg Test: the timed task of placing and removing nine pegs, which is how hand function gets measured when nobody is guessing. The gummy group improved significantly. p = 0.011.
Buttons, keys, a kettle, a jar lid. That is what that test is standing in for.†
Q-Actin® is a patented cucumber extract studied in five published human trials — including placebo-controlled work at 20 mg, the exact dose in each gummy.
Twenty milligrams against two thousand seven hundred. For a hundred and eighty days.
20 mg of Q-Actin® cucumber extract in a sugar-free vegan gummy, to support joint comfort and mobility.† It is the dose used in the published human trials, taken in the evening, which is the timing those trials used.
In a sponsor-funded, 180-day randomised, double-blind, multi-centre trial with no placebo arm — an active comparison against glucosamine-chondroitin rather than against nothing — 20 mg of Q-Actin® a day improved joint comfort, stiffness and function (WOMAC) by 70.3% against its own starting point, while the 2,700 mg glucosamine-chondroitin group improved 32.81% against theirs. 122 people, six months, p<0.05.
Three things we will say plainly about that trial: it is a pooled multicentre pilot rather than a single registration study; its own abstract and results text do not agree on every number; and it dosed 10 mg twice daily, where VFlex gives you 20 mg once in the evening — the same daily total on a different schedule.
One of the five published trials was run in gummy form: 56 people, twelve weeks, double-blind against placebo, with manual dexterity measured directly by the Nine-Hole Peg Test (p = 0.011). Most ingredient evidence is generated on a raw powder and then sold inside a product that was never tested.
Glucosamine is manufactured by grinding shrimp, crab and lobster shells. Q-Actin® is cucumber: no shellfish, no marine contaminants, no animal gelatin — the gummy is set with fruit pectin.†
Supplement Facts
Serving Size: 1 Gummy | Servings Per Container: 30
| Amount Per Serving | % Daily Value | |
|---|---|---|
|
Q-Actin® (Cucumis sativus L. Extract)* Standardized to idoBR1 |
20 mg | ** |
** Daily Value not established.
Other Ingredients: Fructooligosaccharides (FOS), Maltitol, Water, Pectin, Citric Acid, Sodium Citrate, Natural Flavour.
* Q-Actin® is a registered trademark of IminoTech, Inc., USA.
Trials were run on Q-Actin® by its maker, IminoTech, Inc. We send them so you can read the methodology and the limitations yourself.
Glucosamine is manufactured by grinding the shells of shrimp, crab and lobster. That means a permanent shellfish-allergen exposure, and a raw material harvested from water that increasingly carries lead, cadmium, mercury and microplastics.
Q-Actin® is cucumber. No shellfish. No marine contaminants. No animal gelatin — the gummy is set with fruit pectin. Oral LD50 above 5,000 mg/kg, non-mutagenic, cGMP-manufactured and batch-tested.
And you take one, not six.
Everything on this page can be checked. That's the entire pitch.
Inflammatory signalling rises overnight, while you are still. A joint supplement taken with breakfast has largely done its work by the time that happens. Taken about thirty minutes before sleep, VFlex is in circulation when it matters.
Supports morning joint flexibility and helps ease temporary stiffness associated with physical activity.
If it isn’t for you, tell us and we’ll refund it. Keep the canister — nothing to send back. Sixty days is a refund window, not a results window.
60-day refund — opened or not, nothing to send back · Free US shipping · The five papers sent with your order
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Individual results vary. Consult your physician before beginning any supplement. Q-Actin® is a registered trademark of IminoTech, Inc., USA.
SSL Secured
All Major Cards Accepted
Apple Pay & Google Pay
2-Day Shipping Available
